Skip to main content
Edwards Lifesciences Logo

From one heart to over 500,000 lives touched.

Inspiring results hero

Together, we are building a comprehensive body of evidence to drive innovation and advance patient care.

COMMENCE Aortic Trial: Long-Term 10-Year Durability Outcomes

Results at 10 years

The COMMENCE aortic trial provides a decade of follow-up in a large, prospective, non-randomized, multicenter, single-arm, IDE trial exploring the safety and effectiveness of surgical aortic valve replacement (SAVR) with a bioprosthesis utilizing RESILIA tissue. Across US and European clinical sites, 192 patients completed the 10-year visits.1,2

97.9%

Freedom from SVD

97.8%

Freedom from reoperation due to SVD

94.3%

Freedom from valve-related mortality

For more details, download the clinical infographic.

proof-of-ignite
Explore the clinical data

With favorable clinical outcomes, a strong safety profile, and stable hemodynamics performance through 10 years, the COMMENCE aortic trial demonstrates durable results for bioprostheses with RESILIA tissue.

The 10-year data from the COMMENCE aortic trial represent one of the longest follow-ups after SAVR with RESILIA tissue

Eight-Year Outcomes of RESILIA Tissue Valves vs Non-RESILIA Tissue Valves

Results at 8 years

Long-term outcomes compared between RESILIA tissue (n=689; n=239 reconsented) and non-RESILIA tissue (n=258) valves using propensity-matched data from 2 prospective trials in SAVR patients. RESILIA tissue valves significantly outperformed contemporary tissue bioprostheses in SAVR patients.4

99.2%

Freedom from reoperation due to SVD vs 93.9%*

99.3%

Freedom from SVD vs 90.5%*

97.0%

Freedom from all-cause reoperation vs 90.5%*

For more details, download the clinical infographic.

Comparison -year outcomes PDF thumbnail
Explore the clinical data

Clinically stable hemodynamics were observed in the RESILIA tissue valve cohort, supporting strong valve durability through 8 years.

*  Comparator arms: RESILIA tissue valves vs non-RESILIA tissue valves.

Watch Dr Tsuyoshi Kaneko, Chief of Cardiac Surgery at Washington University in St. Louis, present the 8-year follow-up data from this study

RESILIA tissue valves may maximize life expectancy while balancing valve durability over non-RESILIA tissue valves

References

  1. Svensson L, Blackstone E, Bavaria JE, et al. Long-term outcomes following aortic valve replacement with a novel tissue bioprosthesis: 10-year results from the COMMENCE trial. Presented at the American Association for Thoracic Surgery, May 2026.
  2. Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2024;168(3):781-791. doi:10.1016/j.jtcvs.2023.09.047
  3. Akins CW, Miller DC, Turina MI, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg. 2008;85(4):1490-1495. doi:10.1016/j.athoracsur.2007.12.082
  4. Kaneko T, Bavaria JE, Thourani VH, et al. Propensity-adjusted 8-year outcomes following bioprosthetic aortic valve replacement: The influence of novel anticalcification technology. JTCVS Open. 2025;29:101557. doi:10.1016/j.xjon.2025.101557
  5. Salna M, Bavaria JE, Heimansohn D, et al. Seven-Year Results for RESILIA Tissue in Bicuspid Aortic Valve Replacement Patients: Age and Valve Size Considerations. Interdiscip Cardiovasc Thorac Surg. 2025;40(8):ivaf176. doi:10.1093/icvts/ivaf176
  6. Thourani, VH, Puskas JD, Griffith B, et al. Five-year Comparison of Clinical and Echocardiographic Outcomes of Pure Aortic Stenosis with Pure Aortic Regurgitation or Mixed Aortic Valve Disease in the COMMENCE Trial. JTCVS Open. Sept (2024); https://doi.org/10.1016/j.xjon.2024.08.020
Medical device for professional use.

Medical device for professional use.

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com  where applicable).

PP--EU-1509 v1.0